Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in App NL‐G‐F KI mice
Alzheimer's & Dementia · 2026-06 · 22 (6)
DOI: 10.1002/alz.71531 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 03.06.2026. Verfasst von Yo Tsuda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Amyloid beta-Protein Precursor, Hippocampus, Memory Disorders, Neuropeptides. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Dainippon Sumitomo Pharma, Eisai.
Abstract (Originalsprache)
INTRODUCTION Whether cholinergic activity in the septohippocampal network affects cognitive dysfunction via hippocampal cholinergic neurostimulating peptide (HCNP) in Alzheimer's pathogenesis remains unclear. METHODS An Alzheimer's pathogenesis by mutation in amyloid‐beta precursor protein gene ( App NL‐G‐F ) knock‐in (KI) and HCNP precursor protein conditional knockout (HCNP‐pp cKO) mouse model was generated, exhibiting both cholinergic dysfunction and amyloid pathogenesis. Theta power‐related cholinergic function and long‐term potentiation (LTP) were evaluated in App NL‐G‐F KI/HCNP‐pp cKO mice. Molecules associated with the cholinergic/glutamatergic neurons, amyloid beta (Aβ), and inflammation were examined. RESULTS Reduced HCNP levels enhanced cognitive impairment, inhibiting theta power and LTP, although without accompanying pathological changes or inflammation. Decreased N ‐methyl‐D‐aspartate receptor subunit 2A (NR2A), choline acetyltransferase (ChAT), and Vesicular acetylcholine transporter (VAChT) levels were observed in the hippocampus and ChAT in the medial septal nucleus (MSN) of App NL‐G‐F KI/HCNP‐pp cKO mice. DISCUSSION Cholinergic dysfunction in HCNP‐pp cKO mice exacerbates cognitive dysfunction in App NL‐G‐F KI mice. The obtained mouse models are expected to be used to investigate cholinergic dysfunction and amyloid pathogenesis in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, Gifu, Japan.
- Department of Neurocognitive Sciences, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Neurophysiology and Brain Sciences, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Förderung
- Japan Society for the Promotion of Science
- Dainippon Sumitomo Pharma
- Eisai
- Daiichi-Sankyo
- Otsuka Pharmaceutical
Zitieren
APA
Tsuda, Y., Madokoro, Y., Suzuki, K., Ooba, T., Sato, T., Uchida, Y., Nagai-Arakawa, I., Saito, T., Hara, H., Hida, H., & Matsukawa, N. (2026). Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in App NL‐G‐F KI mice. Alzheimer's & Dementia, 22(6). https://doi.org/10.1002/alz.71531
Vancouver
Tsuda Y, Madokoro Y, Suzuki K, Ooba T, Sato T, Uchida Y, et al. Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in App NL‐G‐F KI mice. Alzheimer's & Dementia. 2026;22(6). doi:10.1002/alz.71531
BibTeX
@article{Tsuda2026,
author = {Tsuda, Yo and Madokoro, Yuta and Suzuki, Kengo and Ooba, Takuya and Sato, Toyohiro and Uchida, Yuto and Nagai-Arakawa, Itsumi and Saito, Takashi and Hara, Hideaki and Hida, Hideki and Matsukawa, Noriyuki},
title = {Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in App NL‐G‐F KI mice},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {6},
doi = {10.1002/alz.71531}
}
EUVIMED